LCM
CTXR icon

Laurion Capital Management’s Citius Pharmaceuticals CTXR Stock Holding History

Laurion Capital Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,412
Closed -$55K – 511
2022
Q2 		$55K Buy
+2,412
New +$66.1K ﹤0.01% 419

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return

Laurion Capital Management's CTXR Position: Q3 2022 in Review

Laurion Capital Management sold out of Citius Pharmaceuticals (CTXR) in Q3 2022, closing a stake of 2,412 shares — an estimated $55K sold.

Laurion Capital Management first reported a position in CTXR in Q2 2022 and held it in 1 quarter. The position peaked at $55K in Q2 2022. 56 funds tracked by Wall St. Rank hold CTXR as of Q3 2022.

  • Laurion Capital Management reported no remaining Citius Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Laurion Capital Management sold 2,412 Citius Pharmaceuticals shares in Q3 2022, an estimated $55K.
  • Laurion Capital Management first reported a position in Citius Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Laurion Capital Management's Citius Pharmaceuticals position peaked at $55K in Q2 2022.
  • 56 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2022.

Based on Laurion Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.